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Aims. To compare the results of estrogen and progesterone receptors (ER, PR), and human epidermal growth factor receptor-
2 (HER2) expression status on biopsy and excision specimens and to evaluate the eﬀect of cold ischemia time and/or formalin
ﬁxation on these biomarkers. Methods. Breast carcinomas that were diagnosed between 2007 and 2009 by core needle biopsy, and
subsequently excised in our institution, were included in the study. Data regarding the tumor morphology, grade, and ER, PR,
and HER2 status were retrospectively collected from the pathology reports. Results. Five out of 149 (3.4%) cases with ER-positive
receptor status in the biopsy specimen became ER-negative in the subsequent excision specimen. Nine out of 126 (7.1%) cases
with PR-positive receptor status in the biopsy specimen became PR-negative in the excision specimen. Receptor status change
was predominantly seen in tumors with low ER and PR receptor expression. HER2 results were consistent between biopsy and
excision specimens in all cases tested. Conclusions. Cold ischemia time and/or formalin ﬁxation aﬀect mainly ER and PR testing
with low Allred scores and support the implementation of the ASCO/CAP guidelines. HER2 results, however, were not aﬀected in
our limited number of patients.
1.Introduction
Breast cancer is one of the best examples where antibody-
deﬁned tumor markers are used as both prognostic and pre-
dictive factors. Prognostic factors are independently associ-
ated with the clinical outcome, whereas predictive factors are
independently associated with response or lack of response
to a particular treatment. Estrogen receptor (ER) expression
is a positive prognostic marker of outcome and a strong
predictive marker of response to hormone-based therapies
such as tamoxifen [1, 2]. Similarly, progesterone receptor
(PR) expression is correlated with better prognosis and
higher response to hormone-based treatments and increases
the predictive power of ER [3–5]. Yet another important
marker in the evaluation of breast cancer is the human
epidermalgrowthfactorreceptor-2(HER2;c-erbB-2),which
is a member of the epidermal growth factor receptor family.
HER2 overexpression and/or gene ampliﬁcation have been
shown to be a poor prognostic factor in breast cancer [6, 7].
HER2statusisalsopredictiveforsensitivitytoanthracycline-
based chemotherapies and relative resistance to cytoxan-
based and tamoxifen-based adjuvant therapies [8]. More-
over, it is essential for the therapeutic decisions regarding the
use of agents targeting the HER2 gene product such as the
humanized, monoclonal antibody, trastuzumab [9].
The current standard of care for breast cancer requires
detection of ER and PR status by immunohistochemistry
(IHC) and detection of HER2 status by IHC and/or ﬂuores-
cence in situ hybridization (FISH). There are several factors
that can potentially interfere with the accuracy of results of
these tests including tissue ﬁxation (type of ﬁxative, cold
ischemia time, and duration of ﬁxation), choice of tissue
(core needle biopsy versus excision specimen), choice of
IHC assay, and threshold for interpretation of positivity.2 Pathology Research International
The American Society of Clinical Oncology and College of
American Pathologists (ASCO/CAP) developed guideline
recommendations for tumor marker testing in breast cancer
based on currently available literature to improve the accu-
racy and the reproducibility of these tests [10, 11]. In sum-
mary, they recommended that core needle biopsies should
be preferred for testing if they are representative of the
tumor, cold ischemia time should be kept to less than 1
hour, and samples should be ﬁxed in 10% neutral buﬀered
formalin (NBF; formalin in water, 10% by volume, pH 7.4)
no less than 6 hours and no more than 72 hours to comply
with the panel recommendations for ER and PR testing.
Recommended cold ischemia time for HER2 testing is not
speciﬁcally mentioned but it should be as short as possible,
and specimens should be ﬁxed in 10% NBF no less than 6
and no more than 48 hours.
At our institution, all core needle biopsies have been im-
mediately placed into 10% NBF as a standard procedure
(<1h o u r )f o rm a n yy e a r s .H o w e v e r ,t h e r ew a sn or e c o r d e d
information regarding the cold ischemia time for surgical
specimens before the adaptation of ASCO/CAP guideline
recommendations. Cold ischemia time is estimated to be
more than 1 hour in all specimens. The purpose of this study
is to compare the results of ER, PR, and HER2 expression




This study was approved by the Loyola University Medical
Center (LUMC) Institutional Review Board. We conducted
a pathology database search for all patients with in situ or
invasive breast carcinomas diagnosed by a core needle biopsy
between January 2007 and December 2009. Patients who
underwent subsequent tumor excision (excisional biopsy or
mastectomy) at LUMC were included in the study. Patients
who received treatment between the core needle biopsy
and the surgery were excluded from the study. Cases seen
in pathology consultation, excision specimens without a
biopsy cavity and/or scar, and specimens without diagnostic
tissue or without immunohistochemical stains for hormone
receptors were also excluded from the study. Data regarding
the duration of ﬁxation, tumor morphology, grade, and
hormone receptor and HER2 status were retrospectively
collected from the pathology reports.
2.1. Specimen Collection and Processing. Core needle biopsies
have been routinely placed in 10% NBF at the time of pro-
cedure at the Radiology Department. Therefore, cold ische-
mia time was under 1 hour for all core needle biopsies.
Excisional biopsy (lumpectomy) and mastectomy specimens
have been received by pathology after the completion of the
surgery. There is no record of the time when the specimen
was collected from the patient. Hence, cold ischemia time is
unknown for surgical specimens and estimated to be more
than 1 hour in all specimens. After inking of the margins,
specimens were sliced in 0.5cm thickness and placed in 10%
NBF at the Pathology Department. The duration of ﬁxation
has been routinely recorded for all specimens and complies
with the panel recommendations of 6 to 48 hours.
IHC analysis of ER, PR, and HER2 was performed on the
Benchmark XT staining module (Ventana Medical Systems
Inc, Tucson, AZ). Paraﬃns e c t i o n sw e r ec u ta t5 µma n d
placed on positively charged slides. Slides were incubated in
a7 0 ◦Co v e nf o r2h o u r sf o rE Ra n dP Ra n da i r - d r i e da t
ambient temperature overnight for HER2. CONFIRM anti-
ER (SP1, 1µg/mL), CONFIRM anti-PR (1E2, 1µg/mL), and
PATHWAY anti-HER2/neu (4B5, 6µg/mL) rabbit mono-
clonal antibodies (Ventana Medical Systems Inc) were used
as primary antibodies. Deparaﬃnization, epitope retrieval
via cell conditioning (CC1, Ventana) for 90 minutes, anti-
body incubation at 37◦C or 30 minutes, and counterstaining
with hematoxylin were performed according to the auto-
mated slide stainer protocol. Unstained slides were sent to an
outside laboratory (Genzyme) for detection of HER2 gene
ampliﬁcation by FISH.
2.2. Interpretation and Reporting of the Results. H&E and
IHC studies were evaluated by one or more of the three
experienced breast pathologists. ER, PR, and HER2 staining
was assessed according to ASCO/CAP guideline recommen-
dations [10, 11]. In addition to the positive internal controls,
an external control (breast tumor with known ER, PR or
HER2 positivity, resp.) was evaluated on the same slide with
the diagnostic tissue. Allred scores were calculated for ER
and PR [2]. HER2 FISH results were provided as negative,
equivocal, or positive by the outside lab in concordance with
ASCO/CAP guidelines [10].
2.3. Statistical Analysis. Statistical analyses were performed
using SPSS 11.0.1 (SPSS Inc., Chicago, IL). Descriptive
data were presented as means with standard deviations.
Comparisons among the Allred scores of biopsy and excision
specimens for ER and PR were performed with Wilcoxon
Signed-Rank test. Comparisons among biopsy and excision
ratesofERandPRexpressionwereperformedwithPearson’s
chi-square and Fisher’s Exact tests. Results with a P value less
than 0.05 were accepted as signiﬁcant.
3. Results
We identiﬁed 679 patients based on our database search and
included 190 patients in the study. Patients who had either
biopsy or surgery performed at an outside hospital (n =
320), patients with neoadjuvant chemotherapy (n = 11) and
patients with specimens lacking diagnostic tissue (n = 18)
or tumor marker studies in both specimens (n = 140) were
excluded from the study. Mean age of the patients at the time
of surgery was 62.2±14.0 years and average size of the tumor
based on gross or microscopic evaluation was 2.00±1.70cm.
There were 23 ductal carcinomas in situ (DCIS), 137 invasive
ductal carcinomas, 18 invasive lobular carcinomas, and 12
otherinvasivetumorsincludinginvasivesolidpapillarycarci-
noma, apocrine carcinoma, and metaplastic carcinoma. The
duration of ﬁxation complies with the ASCO/CAP guidelinePathology Research International 3
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Figure 1: Histology and hormone receptor staining of a case with estrogen-receptor (ER-) positive, progesterone-receptor- (PR-) positive
results in biopsy and ER-negative, PR-negative results in subsequent excision. (a) Biopsy, invasive ductal carcinoma, Nottingham Grade III,
hematoxylin & eosin (400x); (b) biopsy, ER (+), Allred score 3 (400x); (c) biopsy, PR (+), Allred score 3 (400x); (d) excision, invasive ductal
carcinoma, Nottingham Grade III, hematoxylin & eosin (400x); (e) excision, ER (−), Allred score 0 (400x); (f) excision, PR (−), Allred score
0 (400x).
recommendations for all specimens; 8.7 ± 3.3 (median: 8,
range: 6–34) hours for biopsies and 22.2 ± 9.2 (median: 26,
range: 6–48) hours for excision specimens (P<0.001). The
duration of ﬁxation was similar between ER-positive and
ER-negative biopsies, ER-positive and ER-negative excisions,
as well as PR-positive and PR-negative biopsies (data not
shown; P>0.05 for all). The duration of ﬁxation was
slightly longer (25.5 ± 8.7 hours) for PR-positive excisions
as compared to PR-negative excisions (21.7 ± 9.8h o u r s ;P =
0.022).
ER status was evaluated in all biopsies and 149 out of 190
(78.4%) were positive (Tables 1 and 2). ER status was eval-
uated in all excision specimens and 144 out of 190 (75.9%)
were positive. Five out of 149 (3.4%) cases with ER-positive
receptor status in the initial biopsy specimen became ER-
negative in the subsequent excision specimen (Figure 1).
Negativestainingwasveriﬁedwithasecondstudyinallcases.
The false-negative rate for the ER receptor on the excision
specimenwas10.9% (P<0.001). Allthecasesthatconverted
fromER-positivetoER-negativehadanAllredscoreof3with
a positivity ratio of 1%. Allred scores of ER-positive receptor
status in biopsies that remained positive in the excision
specimens had an Allred score of 5 and higher. The average
Allred score for ER was 6.1 ± 3.3 among biopsy specimens
and 5.9 ± 3.4 among excision specimens (P = 0.004).
PR status was evaluated in 186 out of 190 biopsies
(97.9%), and 126 out of 186 (67.7%) were positive (Tables 1
and 3). PR status was evaluated in 189 out of 190 exci-
sion specimens (99.5%), and 123 out of 189 (65.1%) were
Table 1: Hormone receptor status of breast cancers in core needle
biopsy and excision specimens.
Discrepancy





(positive/tested) 149/190 144/190 5 0
PR
(positive/tested) 126/186 123/189 9 5
E R :e s t r o g e nr e c e p t o r ,P R :p r o g e s t e r o n er e c e p t o r .





Positive 144 0 144
Negative 5 41 46
Total 149 41 190
positive. There were 14 discrepant results for PR receptors
between the biopsy and excision specimens of the same tu-
mor. Five biopsy cases with negative PR receptors were re-
ported to be PR-positive in the excision specimen. Nine
out of 126 (7.1%) cases with PR-positive receptor status in
the biopsy specimen became PR-negative in the subsequent4 Pathology Research International





Positive 117 5 122
Negative 9 55 64
Total 126 60 186
excision specimen. Negative staining was veriﬁed with a re-
peat study in three cases. The false-negative rate for PR
receptors on the excision specimen was 14.1% (P<0.001).
The cases that converted from PR-positive in biopsies to PR-
negative in excision specimens had a lower Allred score of
4.3 ± 1.9 as compared to other cases that remained positive
(7.0 ± 1.3; P<0.001). The average Allred score for PR
was 4.6 ± 3.4 among biopsy specimens and 4.5 ± 3.4a m o n g
excisions (P>0.05).
Out of ﬁve cases that converted from ER-positive in
biopsies to ER-negative in excision specimens, two had PR-
negative receptors both in biopsies and excisions, two had
PR-positive receptors in biopsy specimens that converted to
PR-negative in excision specimens, and one had PR-positive
receptors in the biopsy specimen that remained PR-positive
in the excision specimen. The latter was the only specimen in
our series with an ER-negative, PR-positive result.
Among the cases with invasive tumors (n = 167),
an IHC evaluation of HER2 status was performed in 164
(98.2%) biopsies. Among these, 15 were positive (3+), 32
were equivocal (2+), and 117 were negative (0 or 1+). Only
19outof32equivocalbiopsieshadfurthertestingwithFISH,
and, out of 19, only one (5.3%) tested positive. Overall,
16 (9.8%) biopsies were classiﬁed as positive, 13 (7.9%)
biopsies were classiﬁed as equivocal, and 135 (82.3%) were
classiﬁed as negative after FISH evaluation. IHC evaluation
of HER2 status was possible in all excision specimens and,
among these, 16 (9.6%) were positive, 123 (73.7%) were
negative, and 28 (16.8%) were equivocal. Twenty-ﬁve out of
28 equivocal specimens were further evaluated by FISH and
two(8%)testedpositive.Therefore,afterFISHevaluation,18
(10.8%) were classiﬁed as positive, 3 (1.8%) were classiﬁed
as equivocal, and 146 (87.4%) were classiﬁed as negative.
Three cases without HER2 evaluation in biopsy specimens
had negative IHC results in their excision specimens. There
was no discrepancy between the IHC and FISH results for
both the biopsy and excision specimens.
Based on the ﬁnal classiﬁcation (considering both IHC
and FISH), there was no clinically signiﬁcant discrepancy for
HER2 status between the biopsy and the excision specimens
of the same tumor. Exact concordancewas seenin 146 (89%)
out of 164 cases. There was one case with an equivocal
IHC result in biopsy and a positive IHC result in excision;
however, FISH analysis of the biopsy was positive and this
casewasnotconsidereddiscrepant.Thereweretwoequivocal
HER2 status in biopsies (equivocal IHC staining, no FISH
evaluation) later classiﬁed as positive (equivocal IHC stain-
ing,positiveFISH)intheexcisionspecimens,whichwerenot
considereddiscrepant.Therewasnodiscrepancybetweenthe
FISH results of biopsies and excisions.
4. Discussion
ER, PR, and HER2 expression status of a breast cancer has
signiﬁcant prognostic and predictive value. Hence, invalid
test results could signiﬁcantly change the therapeutic man-
agement of a patient with potentially negative eﬀects on the
outcome. Along with analytic (choice of assay) and postan-
alytic (choice of cutoﬀs) factors, preanalytic factors play a
signiﬁcant role in the accuracy and precision of these tests.
Allstepsofspecimenhandling,includingcoldischemiatime,
duration of ﬁxation, and type of ﬁxative, have an impact on
the result, and optimization of tissue handling is essential for
clinicalutilityofthesetests.Atourinstitution, allcoreneedle
biopsy materials have been directly placed into 10% NBF
after acquiring and, therefore, cold ischemia time for those
specimens has been minimal. In contrast, cold ischemia time
for the surgical excision specimens has not been recorded
before the adaptation of ASCO/CAP guideline recommen-
dations for specimen handling for hormone receptor testing
in breast cancer and was estimated to be more than 1 hour in
almost all specimens. In this study, we compared surgically
excised tumors with the preceding core needle biopsies from
the same tumor for ER, PR, and HER2 status to evaluate the
eﬀects of cold ischemia time and/or formalin ﬁxation.
We identiﬁed 5 out of 149 patients whose tumors that
wereinitiallyER-positiveincoreneedlebiopsieslaterbecame
ER-negative by IHC in their excision specimen. Similarly, 9
out of 126 patients whose tumors that were PR-positive in
biopsies later became PR-negative by IHC in their excision
specimen. With more than 10% false-negative rates, these
resultsarebothstatisticallyandclinicallysigniﬁcant.Accord-
ing to current treatment algorithms, these patients would be
inappropriatelydeniedhormone-basedchemotherapies,and
their prognoses would be negatively aﬀected if treated based
only on excision specimen results.
Our false-negative results are similar the previous studies
in the literature [12, 13]. A recent study by Uy et al. reported
that25outof152ER-positive corebiopsiesand17outof150
PR-positive core biopsies became ER- and PR-negative in the
mastectomy specimen, respectively [12]. In another study,
Mann et al. reported that concordance rates for ER and PR
status between core biopsy and surgical specimens were 86%
and 83%, respectively [13]. Respective false-negative rates
for ER and PR on surgical specimens in their series of 100
patients were 14% and 15%.
Our results also showed that Allred scores for ER on bi-
opsy specimens were signiﬁcantly higher than those on exci-
sion specimens. This ﬁnding agrees with the previous studies
reporting higher rate of ER staining and Allred scores on
core and incisional biopsy specimens [12–16]. This can be
explained by loss of hormone receptors secondary to various
factors including longer warm and cold ischemia times,
insuﬃcientﬁxationduetolargersizeofmastectomiesand/or
tumor heterogeneity [14, 15, 17–21]. We could not show a
signiﬁcant diﬀerence between the biopsy and excision spec-
imens for PR Allred scores. However, this analysis could bePathology Research International 5
aﬀected by the cases with PR-negative biopsies and corre-
sponding PR-positive excisions. We believe that the initial
PR-negativity of these biopsies was most likely due to sam-
pling. Sampling has been described as a signiﬁcant factor
for false-negative PR results in small biopsies due to more
heterogeneous PR expression of the tumor cells [22].
Higher Allred scores and percentages of staining in bi-
opsy specimens can be explained by better preservation of
the receptor proteins with timely ﬁxation. Delayed formalin
ﬁxation and associated long ischemia times were reported to
be negatively correlated with the hormone receptor expres-
sion in the diagnostic specimens [18, 20, 21]. A decreased
proteinlevelbydelayedﬁxationwasinitiallyshownbyligand
binding assays [18]. Recently, an experimental study on 10
breast cancer cases reported that a progressive delay of ﬁx-
ation was correlated with a progressive decrease of both the
percentage and intensity of ER, PR, and HER2 IHC staining
of tumor cells [20]. Although their numbers were limited to
reach statistical signiﬁcance, they have one case that showed
conversion of positive staining in immediately ﬁxed sample
to negative staining in late-ﬁxed samples. The same group
furtherreportedthatthenegativeimpactofdelayedformalin
ﬁxation is independent of the antibody clone used for the
testing [21]. Another experimental study reported no change
in the ER and PR results of a strongly and diﬀusely ER-
positive, PR-positive breast carcinoma after storage at 4◦C
for four days. However, as they have also mentioned in
their discussion, this ﬁnding may not be extrapolated to the
tumors with weak ER and PR positivity [23].
Our results showed that cases with false-negative IHC
results on excision specimens had lower Allred scores in
biopsy specimens for both ER and PR. All ER-positive
biopsies that became ER-negative in the excision had an
Allredscoreof3,with weakstaining of1%ofthetumorcells.
Similarly, Allred scores of PR-positive biopsies that became
PR-negativeintheexcisionspecimenweresigniﬁcantlylower
than those that remained positive. Because these cases had
only few positive receptors, it is expected that they are
particularlyatriskforfalsenegativity.Toourknowledge,this
is the ﬁrst study comparing the eﬀect of cold ischemia time
on tumor markers with low and high Allred scores in real
patient data.
In our study, there was no clinically signiﬁcant discrep-
ancy between biopsies and excision specimens regarding the
HER2 receptor results as assessed by the combination of IHC
and FISH. There were 10 cases with HER2-equivocal results
in biopsy and HER2-negative results in subsequent excision
specimens. Seven cases had HER2-negative results in biopsy
and HER2-equivocal results in excision specimens, and 1
casehadHER2-equivocalresultinbiopsyandHER2-positive
result in the excision specimen. There was no discrepancy
when the equivocal cases were reclassiﬁed via FISH results
except for the cases without FISH analysis. Nevertheless, the
possibility of the eﬀect of delayed ﬁxation on HER2 results
cannot be entirely ruled out due to the low number of cases.
Apreviousstudycomparingtheresultsofcoreandincisional
biopsies reported a concordance rate of 80% [13]. Seven-
teen out of 20 discrepant cases had HER2-equivocal core
biopsy and HER2-negative surgical specimens. Two cases
had HER2-negative biopsy and HER2-equivocal surgical
specimens and one case had HER2-positive core biopsy and
HER2-negative surgical specimen. Without further FISH
analysis, the clinical signiﬁcance of conversion from equivo-
cal to negative IHC is not clear. Another study evaluating the
IHC and FISH results of the tumor samples that were placed
in a ﬁxative at diﬀerent time intervals reported variable and
inconsistent IHC results in addition to higher numbers of
compromised FISH results with longer cold ischemia times
[20]. Two recent studies reported that cold ischemia time has
no eﬀect on HER2 FISH results [24, 25].
Our study has some limitations due to its retrospective
nature. We had to exclude some cases wherein biopsy or sur-
gery was performed at an outside hospital, patients under-
went neoadjuvant chemotherapy, and/or there was an ab-
sence of diagnostic tissue or tumor marker studies in both
specimens. Not all cases had repeat IHC and FISH studies
on both biopsy and excision specimens, which might induce
a selection bias in our study population. We do not have
accurate data about the cold ischemia time for excision spec-
imens. Although we had data documenting the time that the
specimenwasreceivedbythepathologydepartment,wehave
nowayoftrackingthetimeofcollectionfromthepatientret-
rospectively. However, we strongly believe that cold ischemia
time was more than 1 hour in all excision specimens. Typi-
cally there are no weekend specimens in our institution.
Formalin ﬁxation is expected to be slower in surgical
excision specimens than it is in core needle biopsies due to
the size of the specimens. Although surgical specimens were
sliced before formalin ﬁxation, sections are thicker (0.5cm
versus 0.2 to 0.3cm) and expected to be ﬁxed less eﬃciently
compared to biopsy specimens.
Formalin ﬁxation times were longer for excision speci-
menscomparedtobiopsies,althoughbothgroupswerecom-
pliant with the current ASCO/CAP guidelines. We believe
that longer ﬁxation of larger surgical specimens might have
reduced the number of discrepant cases in our study. Al-
though ASCO/CAP guidelines provide the minimum and
maximum ﬁxation times, further studies are required to
assess the “optimum” ﬁxation times for certain types or sizes
of specimens.
Tumor heterogeneity is a potential problem with the as-
sessment of IHC staining in only one section both in biopsy
and excision specimens. We routinely use the largest tumor
section for IHC studies and cannot entirely rule out the pos-
sibility of a false negative result due to tumor heterogeneity
in specimens.
ASCO/CAP guidelines do not recommend the storage of
slides for more than 6 weeks before analysis. Disadvantages
of archived unstained slides for IHC studies including ER,
PR, and HER2 were previously described by multiple studies
[26, 27]. Our stains were performed and interpreted at the
time of original diagnosis. Therefore, our results are free of
any impact of storage of paraﬃn blocks and slides.
AccurateassessmentofER,PR,andHER2statusofbreast
cancers is critical for the correct assignment of the chemo-
therapeutic regimen. This is also important for the validity
of the clinical studies comparing the therapeutic eﬃcacy of
v a r i o u sa g e n t sa m o n gr e c e p t o rp o s i t i v ea n dn e g a t i v et u m o r s .6 Pathology Research International
Multiple factors starting with the delayed ﬁxation might
indeed explain reports of hormone receptor-negative tumors
responding to hormone-based chemotherapies and HER2-
negative tumors responding to trastuzumab treatment [28,
29].
Ourresultsshowthatcoldischemiatimeand/orformalin
ﬁxation predominantly aﬀect tumors with low ER and PR
receptor expression and support ASCO/CAP guideline rec-
ommendations including the cold ischemia time being less
than 1 hour. We believe that these ﬁndings have implications
forstandardizationofclinicalpracticesduringtheevaluation
of the hormone receptor status. Given the importance of the
accuracy of these tests, all factors that might cause variation
of the results should be clearly listed in the ﬁnal pathology
report and considered during the decision of chemotherapy.
There are no studies regarding the best approach to ER,
PR, and/or HER2 negative tumors when guideline recom-
mendations were not followed during the handling of the
specimen. These results strongly support further studies for
evaluation of such tumors in order to understand clinical
implications of possible false-negative results and the critical
future management strategies.
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